Association of acute symptoms and compliance attitude in noncompliant patients with schizophrenia [1]

Journal of Clinical Psychopharmacology

Volumn 27, Issue 4, 2007, Pages 392-394

  Liu Seifert, Hong ^a   Houston, John P ^a   Adams, David H ^a   Kinon, Bruce J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE;

ADULT; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PRINCIPAL COMPONENT ANALYSIS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUBSTANCE-RELATED DISORDERS; TREATMENT REFUSAL;

EID: 34447498650     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000264986.32733.df     Document Type: Letter

References (11)

1. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
2. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv. 1998;49:196-201.
3. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002;63:1121-1128.
4. Becker MH, Maiman LA. Sociobehavioral determinants of compliance with health and medical care recommendations. Med Care. 1975;13:10-24.
5. Kinon BJ, Hill AL, Liu H, et al. Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia. Int J Neuropsychopharmacol. 2003;6:97-102.
6. Weiden P, Rapkin B, Mott T, et al. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull. 1994;20:297-310.
7. Davis JM, Chen N. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. J Clin Psychiatry. 2001;62:757-771.
8. Loffler W, Kilian R, Toumi M, et al. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment. Pharmacopsychiatry. 2003;36:105-112.
9. Perkins DO, Johnson JL, Hamer RM, et al. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res. 2006;83:53-63.
10. Marder SR, Mebane A, Chien CP, et al. A comparison of patients who refuse and consent to neuroleptic treatment. Am J Psychiatry. 1983;140:470-472.
11. McEvoy JP, Howe AC, Hogarty GE. Differences in the nature of relapse and subsequent inpatient course between medication-compliant and noncompliant schizophrenic patients. J Nerv Ment Dis. 1984;172:412-416.